Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.
Douillard JY, Skarin A, Baselga J, Natale R, Giaccone G, Maddox A, Heyes AE. Improvement in disease-related symptoms and quality of life (QOL) in patients treated with advanced non-small cell lung cancer (NSCLC) treated with zd1839 in ideal1 and ideal2. Poster presented at the European Society for Medical Oncology; October 2002. Nice, France.
Lewis B, Silberman C, Heyes AE. Side effects of chemotherapy among patients with ovarian cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting; May 2002. Washington, DC.
Dennison CR, Leidy NK, Silberman C, Heyes AE. Interpretation of quality of life data from a clinician's point of view: getting to the clinically meaningful change. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.
Leidy NK, Jonas D, Silberman C, Margolis MK, Heyes AE. What does it all mean? Using health-related quality of life data to interpret treatment outcomes. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.
Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.